中西医结合单元疗法对于急性冠脉综合征患者的临床成本效果分析

目的:探讨中西医结合单元疗法治疗急性冠脉综合征(ACS)的临床成本效果。方法:选取2012年2月～2013年2月于我院住院治疗的120例ACS患者,随机分为观察组和对照组各60例。所有患者均给予常规中西医药物治疗,观察组在此基础上进行中医特色的情志干预、健康教育、康复指导等辅助治疗。对两组进行成本-效果分析。结果:120例患者中6例脱落,其中观察组4例,对照组2例。观察组总有效率为92.8%,对照组总有效率为79.3%,观察组疗效显著优于对照组,P<0.05。观察组成本效果比为123.79元,对照组成本效果比为154.30元,观察组低于对照组。结论:中西医结合单元疗法治疗ACS经济、有效,值得临床推广。

Cost-effectiveness Analysis on Integrated Cell Therapy in Treating ACS

Objective： To study the cost-effectiveness of integrated cell therapy in treating acute coronary syndrome （ACS）. Methods： From February 2012 to February 2013, 120 cases of ACS patients in our hospital were selected and randomly divided into observation group and control group, 60 cases in each. All patients were given conventional western medicines, while patients in the observation group were applied to TCM which features emotional intervention, healthcare education, rehabilitation guidance and other similar adjuvant therapies. An analysis of the cost-effectiveness of both groups was conducted. Results： In total, 6 patients witnessed rupture, 4 were from the observation group and 2 from the control group. The total effective rate of the observation group and the control group were 92.8% and 79.3% respectively, the total effective rate of the observation group was higher than that of the control group, there was statistically significant difference between the two groups （P〈0.05）. And the costs of the observation group and the control group were 123.79 ynan and 154.30 yuan respectively, the observation group was proved better cost-effectiveness than that of the control group, there was statistically difference between the two groups. Conclusion： Integrated cell therapy in treating ACS is more economical and effective, and should be adopted in wider clinical treatment.